U.S. Biotech Industry Analysis
UpdatedJul 04, 2024
DataAggregated Company Financials
Companies566
- 7D-2.7%
- 3M-0.8%
- 1Y6.9%
- YTD-1.0%
Over the last 7 days, the Biotech industry has dropped 2.7%, driven by AbbVie declining 4.3%. In the past year, the industry has gained 6.9%. Earnings are forecast to grow by 24% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 04 Jul 2024 | US$1.1t | US$164.5b | -US$27,946,912,225.84 | 27.9x | -40.1x | 6.8x |
| Sat, 01 Jun 2024 | US$1.1t | US$164.6b | -US$26,677,227,566.32 | 27.4x | -41.6x | 6.7x |
| Mon, 29 Apr 2024 | US$1.1t | US$164.6b | -US$27,372,800,636.09 | 22.6x | -39.1x | 6.5x |
| Wed, 27 Mar 2024 | US$1.2t | US$164.4b | -US$23,792,606,116.02 | 21.2x | -48.8x | 7.1x |
| Fri, 23 Feb 2024 | US$1.2t | US$169.0b | -US$20,212,652,991.58 | 13.2x | -57x | 6.8x |
| Sun, 21 Jan 2024 | US$1.4t | US$204.8b | -US$22,506,538,466.00 | 18.5x | -63.3x | 7x |
| Tue, 19 Dec 2023 | US$1.4t | US$204.7b | -US$22,117,247,361.00 | 19.2x | -61x | 6.6x |
| Thu, 16 Nov 2023 | US$1.2t | US$204.7b | -US$22,143,559,902.00 | 18.4x | -55.1x | 6x |
| Sat, 14 Oct 2023 | US$1.3t | US$207.3b | -US$13,141,713,262.00 | 16.6x | -96.4x | 6.1x |
| Mon, 11 Sep 2023 | US$1.3t | US$207.5b | -US$12,633,744,533.00 | 17.4x | -101x | 6.1x |
| Wed, 09 Aug 2023 | US$1.3t | US$206.4b | -US$12,500,248,802.00 | 16.4x | -101x | 6.1x |
| Fri, 07 Jul 2023 | US$1.1t | US$186.2b | -US$16,056,868,924.00 | 13.2x | -69.5x | 6x |
| Sun, 04 Jun 2023 | US$1.1t | US$185.9b | -US$16,014,255,509.00 | 11.4x | -71.1x | 6.1x |
| Tue, 02 May 2023 | US$1.2t | US$197.0b | -US$6,677,740,450.00 | 14x | -175.7x | 6x |
| Thu, 30 Mar 2023 | US$1.1t | US$198.3b | -US$4,280,712,821.00 | 13.8x | -266.8x | 5.8x |
| Sat, 25 Feb 2023 | US$1.1t | US$200.5b | -US$3,797,679,065.00 | 14.2x | -295.4x | 5.6x |
| Mon, 23 Jan 2023 | US$1.2t | US$203.8b | US$1.8b | 14.4x | 655.9x | 5.7x |
| Wed, 21 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.6x | 704x | 5.7x |
| Fri, 18 Nov 2022 | US$1.1t | US$202.2b | US$1.2b | 14.7x | 921.2x | 5.5x |
| Sun, 16 Oct 2022 | US$1.0t | US$206.0b | US$5.4b | 15.6x | 194.3x | 5.1x |
| Tue, 13 Sep 2022 | US$1.1t | US$206.9b | US$5.9b | 15.8x | 185.7x | 5.3x |
| Thu, 11 Aug 2022 | US$1.1t | US$208.3b | US$5.7b | 16.6x | 196.3x | 5.4x |
| Sat, 09 Jul 2022 | US$1.1t | US$211.5b | US$10.8b | 17.4x | 102.3x | 5.2x |
| Mon, 06 Jun 2022 | US$1.0t | US$212.8b | US$11.3b | 16.4x | 88.7x | 4.7x |
| Wed, 04 May 2022 | US$1.0t | US$201.1b | US$7.4b | 17.2x | 140.3x | 5.2x |
| Fri, 01 Apr 2022 | US$1.3t | US$221.5b | US$11.4b | 19.1x | 111.5x | 5.7x |
| Sun, 27 Feb 2022 | US$1.2t | US$222.9b | US$10.9b | 19.5x | 113.2x | 5.5x |
| Tue, 25 Jan 2022 | US$1.2t | US$212.0b | US$2.5b | 23.8x | 496.5x | 5.8x |
| Thu, 23 Dec 2021 | US$1.4t | US$212.0b | US$2.8b | 27.2x | 511.5x | 6.8x |
| Sat, 20 Nov 2021 | US$1.4t | US$212.2b | US$3.3b | 27.3x | 442.8x | 6.8x |
| Mon, 18 Oct 2021 | US$1.5t | US$196.3b | -US$2,601,699,037.00 | 23.6x | -565.4x | 7.5x |
| Wed, 15 Sep 2021 | US$1.6t | US$196.4b | -US$2,312,118,480.56 | 21.6x | -682.1x | 8x |
| Fri, 13 Aug 2021 | US$1.6t | US$197.0b | -US$1,662,914,785.58 | 22.7x | -936x | 7.9x |
Price to Earnings Ratio
-1063.1x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.1x is lower than the industry's current PS ratio of 6.8x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Revenues have also declined 5.8% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 1.09% | |
| Healthcare | -1.72% | |
| Biotech | -2.66% | |
| Biotech | -2.66% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| SGEN Seagen | US$228.74 | 4.5% +US$1.8b | 76.5% | PS18.8x | |
| GRPH Graphite Bio | US$22.26 | 539.7% +US$1.1b | 861.6% | PB7.1x | |
| IMGN ImmunoGen | US$31.23 | 6.6% +US$516.6m | 617.9% | PS29.1x | |
| ALNY Alnylam Pharmaceuticals | US$248.68 | 1.4% +US$444.0m | 29.1% | PS15.7x | |
| TALS Talaris Therapeutics | US$27.20 | -4.9% US$430.9m | 91.5% | PB3.7x |